Liver Specialists of Texas RSS Feed

Hepatitis C Research Opportunities with Dr. Joseph Galati: 2013

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 20 Jan 2013 04:00:00 GMT

Listed below are the updated hepatitis C research protocols that Liver Specialists of Texas and Dr. Galati are currently conducting. The studies are in various stages of enrollment, and some may have already met the limit of how many patients we can enroll. A PDF version is available here.

New studies are being added every few weeks, so depending on your situation, and past experience with hepatitis C treatment, new opportunities may be available soon.

Currently, the ongoing studies are making use of both interferon based therapies, as well as interferon-free therapies. It is probable that the next wave of FDA approvals will be for the interferon-free protocols.

Kindly call Dee Wade at 713-794-0700 to inquire about hepatitis C research opportunities.

Research Specialists of Texas

List of Ongoing Studies

No.	Sponsor	Protocol #	Protocol Title:	Status
1	Abbott	M12-114	A Blinded Randomized, Placebo-Controlled, Dose-Ranging study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination with Peginterferon a-2a and Ribavirin (pegINF/RBV) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.	Open/Follow Up
2	Hoffman-La Roche, Inc.	598-505	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Chronic Hepatitis C Infection.	Open/Follow Up
3	Bristol Myers S	AI444-038	Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection.	Open/Follow Up
4	Bristol Myers S	AI444-052	A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir In combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment- Naïve Patients with Chronic Hepatitis-C	Open/ Follow Up
5	Bristol Myers S	AI443-1014	Open-Label, Multiple Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Co administration of BMS-650032, BMS-7900052, and BMS-791325 when administered for 24 or 12 weeks in Treatment-Naïve Subjects Infected with Hepatitis C Virus Genotype 1	Open/Enrolling
5	Gilead	GS-US-337-0102	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir /GS-5885 Fixed-Dose Combination+ Ribavirin for 12 or 24 Weeks in Treatment-Naïve Subjects with Chronic HCV Genotype 1 Infection	Open/ On drug Treatment/FU
6	Gilead	GS-US-334-0110	A Phase 3, Multicenter, Open Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Week in Treatment-Naïve Subjects with Chronic Genotype 1,4, 5, or 6 HCV Infection	Open/ Follow Up
7	Gilead	GS-US-248-0121	A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV) in Treatment-Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype	Open/Follow UP
8	Gilead	GS-US-248-0122 (Registry Study)	A Long Term Follow Up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic HepatitisC Infection	Open
9	Gilead	GS-US-248-0123 (Registry Study)	A Long Term Follow up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C	Open
10	Gilead	GS-US-256-0124	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection	Open/ subjects completed study.
11	Gilead	GS-US-196-0140	A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection	Open/ Subjects finished Study.
12	Gilead	GS-US-256-0148	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C	Open/ Follow up 2 Subjects
13	Gilead	GS-US- 337-0109	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 Weeks in Treatment-Experience Subjects with Chronic Genotype 1 HCV Infection	Open/ Screening
14	Gilead	P7977-1231	A Phase III Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 weeks compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment Naïve Patients with Chronic Genotype 2or 3 HCV Infection	Open/ Follow Up
15	U. Florida/U. NC	HCV-TARGET	Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study	Open/ Ready for Screening
16	Beckman Coulter	HCV-01-11	Multicenter, Prospective Evaluation of the Beckman Coulter DxN-HCV Viral Load Assay as an Aid in the Management of HCV- Infected Individual Undergoing Antiviral	Open/Ready for Screening
17	Merck	5172-003	A Dose Ranging Study to Test the Safety, Tolerability and Effectiveness of Different Doses of MK-5172 When Given with Peginterferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection	Open/ Follow Up
18	Merck	7009-028	A Phase 2 Open Label Study of MK 7009 Administered Concomitantly with Pegylated Interferon Alfa 2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials	Open/ Follow Up
19	Merck	5172-017 (Roll Over)	A Long Term Follow Up Study to Evaluate the Durability of Virologic Response and /or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have been Previously Treated with MK5172 in a Prior Clinical Trial	IRB Approved. Sponsor Site Activation.
20	Novartis	CDEB025A2301	A Randomized Double Blind,Placebo- Controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination with Peginterferon alpha 2a (PEG-IFN) and Ribavirin in hepatitis C Genotype 1 treatment naïve patients.	Open/ Follow Up
21	Novartis	CDEB025A2312 (Roll Over)	A Multi-Centre 3 Year Follow Up Study to assess the Durability of Sustained Virologic response in Alisporivir treated Chronic Hepatitis C patients	Open/ Follow Up
22	Novartis	CDEB025A2313 (Roll Over)	A Multi-Centre 3 Year follow up study to assess the viral activity in patients Who failed to achieve sustained virologic response in Novartis sponsored Alisporivir –studies for chronic Hepatitis C patients	Open
23	Schering-Plough	P05063	Term Follow Up of Subjects in a Phase 1,2,or 3 Clinical Trial in Which Boceprevir or Narlaprevir was administer red for the treatment of Chronic Hepatitis C	Open/ Follow Up
24	Schering-Plough	P05514	A single Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in PREVIOUS Schering-Plough Boceprevir Studies	Open/ Subjects Completed study
25	Tibotec	TMC435-TiD16-C213	A Phase III Open Label Trial of TMC435 In Combination with Peginterferon And Ribavirin for HCV Genotype 1 infected Subjects who Participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007) or who received short term (up to 14 days) direct acting antiviral treatment for hepatitis C infection in a selected Jansen R&D Ireland-Sponsored phase I Study.	Open
26	Tibotec	TMC435-TidP16-C216	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon α-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve, genotype 1, hepatitis C-infected subjects.	Open/ Subjects Completed study
27	Tibotec	TMC435HPC3007	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy.	Open/ Subjects Completed study
28	Tibotec	VX-950-C211	A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection.	Open/Subjects Completed Study Close out visit on 1/31/13
29	Salix Pharmaceuticals, Inc.	RFHE4044	A Multicenter, Randomized, Open, Label, Active Controlled, Trial To Evaluate The Safety And Efficacy If Rifaximin 550 MG With and Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy	IRB Approved Waiting Site Activation.

As of 1/18/13

19-Jan-13 10:00 PM

Dr. Galati and Liver Specialists of Texas: An Introductory Video

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 12 Aug 2012 04:00:00 GMT

Below is a brief video produced by Liver Specialists of Texas discussing the various services that Dr. Galati and his staff perform.

11-Aug-12 11:00 PM

Liver Specialists of Texas is Moving Office Locations

Joseph Galati, M.D. - noemail@texasliver.com — Wed, 13 Jun 2012 20:00:00 GMT

Effective June 14, 2012, our office location is relocating.

Read move about the move and new location details.

13-Jun-12 3:00 PM

Liver Specialists of Texas Newsletter 2-Jun-12

Joseph Galati, M.D. - noemail@texasliver.com — Sat, 02 Jun 2012 06:02:06 GMT

Untitled Document

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, jobs and more from our membership.

Calendar Events
Articles

Calendar Events for 2-Jun-12 to 1-Sep-12

Liver Specialists of Texas is Moving
Day: Thursday 14-Jun-12 8:00 AM to Monday 18-Jun-12 8:30 AM
Location: Liver Specialists of Texas 6560 Fannin Street, Suite 2050 Houston, TX 77030
Mapquest | Add to Calendar

Articles for 3-Apr-12 to 2-Jun-12

Colonoscopy Bowel Prep Video

This video shows the importance of following directions.

Colon Polyp Removal Video

This is a great video we produced showing the value of colonoscopy.

New Facts on HCV

The CDC released new recommendation regarding the testing of HCV, regardless of risk factors.

Frozen Fruits and Vegetable: A Great Alternative

Yes-frozen fruits and vegetables are healthful for you.

Portion Control Guide

A nice article from WebMD.

Remember, our office is moving June 14-18, 2012. Our office will be closed while we set up the new location. Our staff will be available through the answering servive around the clock for all our patients.

We are still evaluating patients for HCV research studies. You can contact Herman Ortiz in our research office. Both naive and retreatment protocols are available.

Remember: Colon Cancer is the third leading cancer in adults. It can be prevented with screening colonoscopy. Contact our office to make an appointment. All adults 50 years of age and older need to be screened; African Americans need to start screening at 45 years old. If you have a family history of colon cancer, you are at increased risk for developing colon cancer.

Your Health First, our weekly radio program, airs every Sunday evening at 7:00 p.m. on Clear Channel's 740 KTRH. It is also streamed on iHeart radio (www.iheartradio.com).

Stay up to date with our RSS feeds.

2-Jun-12 1:02 AM

Colonoscopy Preparation: Importance of Following Directions

Joseph Galati, M.D. - noemail@texasliver.com — Sat, 02 Jun 2012 04:00:00 GMT

This video shows you the importance of following directions while you prepare for a colonoscopy.

1-Jun-12 11:00 PM

Dr. Galati Discusses Fruits and Vegetables

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 29 Jan 2012 18:00:00 GMT

In this video blog, Dr. Joe Galati discusses frozen fruits and vegetables, and how to make the best selection at the food store.

View the You Tube Video here.

29-Jan-12 12:00 PM

Psychiatric Side Effects of Hepatitis C Therapy: Parts 1 and 2

Joseph Galati, M.D. - noemail@texasliver.com — Fri, 11 Nov 2011 14:00:00 GMT

Our latest video, as part of the Hepatitis C Education Program, is a two-part video featuring Dr. Jennifer Pate, a psychiatrist specializing in the care of patients with chronic liver disease.

The video blog can be viewed here for more details.

11-Nov-11 8:00 AM

Hepatitis C Treatment: Side Effects Management with Dr. Saira Khaderi

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 02 Oct 2011 04:00:00 GMT

In this You Tube video, Dr. Khaderi discussed several of the commonly encountered side effects related to hepatitis C therapy with interferon, ribavirin, and the new protease inhibitors.

To view the video on our You Tube Channel, click here.

1-Oct-11 11:00 PM

Liver Specialists of Texas Newsletter 21-Sep-11

Joseph Galati, M.D. - noemail@texasliver.com — Thu, 22 Sep 2011 13:03:30 GMT

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, and more from our membership. We all appreciate your interest in our practice, and learning more about liver disease, new treatments that are available, health and wellness, and the prevention of disease.

Here is the latest from Liver Specialists of Texas.

Colon Cancer Video: Colon cancer is the number three cancer that adults are at risk for. We recently posted a video that is a perfect example of a patient who neglected rectal bleeding, only to find out there was a large polyp looming in his colon. To view the video, click here.

New Hepatitis C Research Opportunities: We continue to participate in clinical research studies for hepatitis C that are available for those either naive to HCV therapy (never treated) or those that have experience with therapy and never fully cleared the virus. One of the new studies is specificially researching African American and Latino adults with hepatitis C. If interested, you can contact our office for details. To learn more, click here.

Inside Look at Liver Transplant Surgery: View photographs of a liver transplant performed a couple of years ago, performed by Dr. Mark Ghobrial, and photographed by Dr. Galati. To view the video, click here.

New FDA Approved HCV Therapy-What You Need to Know, A Podcast: Listen to Dr. Galati discuss the new hepatitis C therapies recently FDA approved. Listed here.

Dietary Fiber: By request, one of the most popular downloads, this article reviewed a plan to increase your dietary fiber. With planning, you can increase your daily fiber to 30-40 grams. Start increasing your fiber by clicking here.

Tune in to Your Health First: Every Sunday evening at 7:00 p.m., tune into Your Health First, Dr. Galati's weekly radio program that discusses current health and wellness topics, with experts from around the world. Listen live at 740 KTRH or on the web at www.ktrh.com.

Staff Profile-Saira Khaderi, M.D.: Dr. Saira Khaderi has been with Liver Specialists of Texas for 1 year, and her presence has enhanced the patient experience greatly. Dr. Khaderi this year will be developing a specialized clinic for those individuals with non-alcoholic fatty liver disease. Deatails on this will follow in the next few months.

Stay up to date with our RSS feeds.

22-Sep-11 8:03 AM

Dr. Saira Khaderi Discussed Liver Disease

Joseph Galati, M.D. - noemail@texasliver.com — Tue, 17 May 2011 00:00:00 GMT

16-May-11 7:00 PM

Job Opportunity: Internist Needed

noemail@texasliver.com — Mon, 25 Jan 2010 14:00:00 GMT

Houston Based Liver Specialists of Texas is Seeking Internists for Their Growing Hepatology and Liver Transplant Program

Internists are needed to expand within a busy clinical Hepatology and Liver Transplant practice, caring for the Internal Medicine needs of patients with all facets of liver disease. Disease management of hypertension, renal disease, hyperlipidemia, obesity, metabolic syndrome, and endocrine disorders in a supportive environment, located in the world’s largest medical center, has openings for April, July, and December 2010.

Houston, TX, January 25, 2010: Internist needed for Hepatology and Liver Transplant Program. Located in Houston’s world-famous Texas Medical Center, we are seeking an energetic BC/BE internist to join a well established and respected program.

This physician will care for the internal medicine needs of patients with liver disease and recipients of liver transplants in an integrated fashion. Clinical support from hepatologists, surgeons, hospitalists, and Nurse Practitioners and Physician Assistants makes this a rewarding work environment. This private practice opportunity is affiliated with a major academic, research, and teaching hospital.

Competitive salary guarantee, generous benefit and retirement package, relocation allowance, and partnership opportunity. Houston and surrounding communities are family oriented with good schools and a stable economy, boasting a reasonable housing market. Contact Jeff Toal at 714.794.0700; recruiter@texasliver.com.

New Hepatitis C Research Study to Begin: Update September 2009

noemail@texasliver.com — Thu, 25 Sep 2008 23:00:00 GMT

Dr. Joseph S. Galati and Liver Specialists of Texas are pleased to announce the start of a new investigational study for patients with hepatitis C. As of September 2009, we will be having additional investigational studies for patients with hepatitis C. The studies are classified for patients based on any prior treatment for HCV. Naive patients have never received any form of anti-viral therapy for hepatitis C. This would include Rebetron, Intron A, Ribavirin, PEG-Intron, Pegasys, or Infergen. Other classes of patients will include those previously treated with any of the above drugs. Further, patients will be classified as either responder-relapsers, or non-responders. Once we are able to screen your records, we can detwrmine if you could participate in any of the studies. There are several large companies sponsoring these studies, with a number of very exciting medications that will be used. The basic inclusion criteria for these study include: male or female...

Clinical Research Coordinator

Sat, 15 Jan 2011 00:25:08 GMT

Title: Clinical Research Coordinator
Description:

Research Specialists of Texas is seeking a qualified clinical research coordinator to work on ongoing clinical research studies in hepatology.

Required Experience:

Three years of clinical research.

Education Required: High School, college
Planned Duration of Employment: Full Time
Salary($): $30,000 - $45,000
Position reports to: Medical Director

Contact info:

Dr. Joseph Galati Galati (Add to Contacts)

Liver Specialists of Texas

6624 Fannin Street, Suite 1990

Houston, TX 77030
US

Internist

Wed, 22 Oct 2008 05:00:00 GMT

Title: Internist
Description:

Internist needed for Hepatology and Liver Transplant Program. Located in Houston’s world-famous Texas Medical Center, we are seeking an energetic BC/BE internist to join a well established and respected program. This physician will care for the internal medicine needs of patients with liver disease and recipients of liver transplants in an integrated fashion.

Clinical support from hepatologists, surgeons, hospitalists, and PA’s makes this a rewarding work environment. This private practice opportunity is affiliated with a major academic, research, and teaching hospital. Competitive salary guarantee, generous benefit and retirement package, relocation allowance, and partnership opportunity. Houston and surrounding communities are family oriented with good schools and a stable economy boasting a reasonable housing market.

Contact Jeff Toal at 714-794-0700; jtoal@texasliver.com.

Required Experience:

Completed approved ABIM Internal Medicine Residency program
BE/BC
U.S. Citzenship required

This Job Requires the Follow Skills:

N/A

Education Required: Medical School
Planned Duration of Employment: Full Time
Position reports to: Chief Medical Officer

Contact info:

Jeff Toal (Add to Contacts)
(713) 794-0700
Fax (713) 794-0610

Liver Specialists of Texas

6624 Fannin Street, Suite 1990

Houston, TX 77030
US

Free Hepatitis C Testing

Mon, 03 Jan 2011 21:37:30 GMT

Fill out this form to receive more information about free Hepatitis C testing.

31 Days of Wellness

Mon, 03 Jan 2011 19:17:23 GMT

Start the new year with a month of wellness in January.

Latest Liver Podcast Episodes

Thu, 02 Dec 2010 16:22:40 GMT

Listen to Dr. Galati's latest health and wellness podcasts.

Research and New Treatments in Hepatitis C

Thu, 02 Dec 2010 16:21:21 GMT

Learn more about the latest treatments and therapies for Hepatitis C patients.

Breaking News in Hepatitis C and Liver Disease

Thu, 02 Dec 2010 16:21:03 GMT

Get the latest information about research in Hepatitis C and liver disease.

Fatty Liver Disease

Thu, 02 Dec 2010 16:20:01 GMT

Learn more about fatty liver disease.

Liver Specialists of Texas with Dr. Joseph Galati: What is Clinical Research

Sun, 20 Jan 2013 04:56:30 GMT

Clinical trials are research studies that test how well new medicines work in people. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease. People who take part in liver clinical trials have an opportunity to contribute to knowledge of, and progress against, all facets of liver disease. Participants also receive up-to-date care from experts. Every clinical trial has a protocol, or action plan, for conducting the trial. The plan describes what will be done in the study, how it will be conducted, and why each part of the study is necessary. Each study has its own rules about who can participate. Studies need volunteers with a certain type of liver disease, including hepatitis C, hepatitis B, ascites, hepatic encephalopathy, or liver cancer. Some studies need healthy people. Others want just men or just women. People who volunteer for a clinical trial will have the opportunity to have the potential risks,...

New Hepatitis C Studies are Now Available at Liver Specialists of Texas: Updated list for 2013

Sun, 20 Jan 2013 04:54:19 GMT

Updated for 2013. Here is the list of current studies. Contact our office at 713-794-0700 for details. Hepatitis C Research: New Therapies for Patients Previously Treated with Interferon and Ribavirin, and Those Naive to Antiviral Therapy Opportunities are available to participate in clinical research protocols through Liver Specialists of Texas and Research Specialists of Texas. Update: New Hepatitis C Drugs Approved: read more About half of all people with chronic hepatitis C virus (HCV) infection achieve a sustained virological response (SVR) or undetected HCV, with the standard treatment of pegylated interferon plus ribavirin; rates are even lower for patients with difficult-to-treat HCV genotype 1. Researchers have studied various antiviral agents that directly target various stages of the HCV lifecycle. Namely protease inhibitors have shown promising results. For patients who have been previously treated with Pegylated...

Liver Specialists of Texas: Our Staff

Wed, 15 Aug 2012 12:40:55 GMT

Staff Members

Delores Wade: Practice Manager

Lauren Thomas, R.N.: Nurse Practitioner

Kathy Loring, R.N.: Nurse Practitioner

Geraldine Galati, R.N.: Clinic Nurse

Aracelli Diaz: Medical Assistant

Mary Rodriguez: Scheduler

Sylvia Nada: Front Desk/Reception

Charlene Gonzales: Research Coordinator

Anne McCombs: Research Coordinator

Wendy Oehlman: Research Coordinator

Wilma Regalado: Research

Nyesha Jordan: Billing/Collection

Research Specialists of Texas 2010

TIEC Open House Photo Album

Liver Specialists of Texas: Our Services

Wed, 27 Jun 2012 13:33:00 GMT

Liver Specialists of Texas provides a wide range of specialized care to patients with digestive and liver disorders. Our main office, located in Scurlock Tower, a 4566 square foot facility, with a spacious waiting room, 7 examinations rooms, a patient/family education classroom, and physician consultation offices. Our warm receptive staff is available for all of your needs. At this location, all of the outpatient consultations take place. Detailed medical histories are obtained along with a thorough physical examination. Old medical records are reviewed by the physicians, as well as previously performed x-rays on lighted view boxes and liver biopsies on a microscope in the office. When necessary, these x-rays and biopsies are reviewed directly with the patient. A full report to your referring physician is dictated immediately once the visit is complete. For foreign visitors, a wide range of interpreter services is available. Patients that require hospitalization for more...

Our Location

Wed, 13 Jun 2012 20:37:48 GMT

Please note we have moved locations effective June 14, 202

6560 Fannin, Suite 2050
Houston, Texas 77030
Tel: 713-794-0700

For a map to our office, please click here. (OpensGoogle Maps in new window)

Address:
6560 Fannin Street

Scurlock Tower
Suite 2050
Houston, Tx 77030
Office: 713-794-0700
Fax: 713-794-0610

Liver Specialists of Texas: Patient Forms

Sat, 02 Jun 2012 04:43:09 GMT

New patients that have been scheduled an appointment with Dr. Galati can download the following forms needed for proper processing and documentation. To save time the day of your visit, it is best if they are filled in ahead of time and bring them with you the day of the appointment. This will reduce the amount of time filling out forms in the office. If you have any questions regarding these forms, feel free to contact Liver Specialists of Texas at 713-794-0700. Our staff will be happy to assist you. Download patient forms here Additional patient forms are posted below. Gatoraide Colonoscopy Bowel Preparation MoviPrep Colonoscopy Bowel Preperation Patient Responsibility Policy Office Policy Office Financial Policy Office HIPPA Release Lab One Houston Locations Quest Lab Houston Locations Quest Lab Sugar Land Locations Quest Lab Woodlands/Conroe Laboratory Corporation of...

Update: New HCV Drugs Approved-Boceprevir and Telaprevir

Wed, 25 May 2011 18:11:39 GMT

Over the past week, two new drugs have been FDA approved.

Saira Khaderi, M.D., MPH

Tue, 17 May 2011 18:10:57 GMT

Dr. Saira Khaderi has joined Liver Specialists of Texas. Dr. Joseph Galati is pleased to announce that Dr. Khaderi has joined Liver Specialists of Texas, increasing patient access to specialized liver care, from one of America's largest liver practices. Saira Khaderi, M.D. was born in Indiana but moved to Houston at a young age. She attended the University of Houston and graduated Magna Cum Laude in 1999 with a major in Biology and minor in Chemistry. In 2001 Saira completed her Masters in Public Health from the University of Texas School of Public Health. She attended medical school from 2001-2005 at the University of Texas Medical Branch in Galveston. In 2008, Dr. Khaderi completed her Internal Medicine Residency at the world renowned Cleveland Clinic Foundation. It was there...

Liver Failure

Fri, 29 Apr 2011 02:42:47 GMT

Liver failure or fulminant hepatic failure is a condition where a person with no preexisting liver disease develops severe liver dysfunction over a matter of days or weeks. Fulminant liver failure is associated with a high mortality rate and is a clear indication for liver transplantation.

The cause of liver failure is quite varied but includes medications, certain infections, trauma, alcohol, disruptions in proper flow of blood to the liver, and unfortunately, there are causes of liver failure that never had a clear identifiable cause.

Patients with liver failure rapidly develop abnormal liver chemistries associated with signs of liver insufficiency associated with the development of ascites [fluid in the abdomen], fatigue, abdominal pain, and most importantly, the development of hepatic encephalopathy, which is a confusion state that is associated with severe liver dysfunction.

Patients with suspected liver failure need to be transferred immediately to a liver center specializing in transplantation where the best therapies can be offered.

Fatty Liver

Sat, 19 Feb 2011 03:24:20 GMT

Some individuals can develop fatty liver. Most people who do not abuse alcohol and have fatty liver are obese. The term that has been accepted is non-alcoholic fatty liver disease (NAFLD). Fatty liver is called steatosis, and fatty liver with liver inflammation is called or steatohepatitis. Steatosis and steatohepatitis can be caused by alcohol and other drugs and can also sometimes occur in patients with diabetes mellitus. The factors that determine who will develop fatty liver are not known. Some mildly obese and occasional non-obese patients will develop fatty liver while some who are severely obese will not. There is a direct relationship between the metabolic syndrome and NAFLD. Patients with fatty liver or steatohepatitis usually present to a physician with unexplained elevations in the serum aminotransferase (ALT/AST) activities. Serum alkaline phosphatase and gamma-glutamyltranspeptidase (GGTP) activities can also be elevated. The patient is usually 10% or more above...

Lorem ipsum survey

noemail@texasliver.com — Fri, 10 Aug 2007 18:51:28 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

Ut wisis enim ad minim veniam, quis nostrud exerci

Release Date: 10-Aug-07 1:51 PM
Expiration Date: 10-Nov-07 1:51 PM

Ut wisis enim ad minim veniam, quis nostrud exerci

Does everyone need a liver biopsy?

Sat, 19 Feb 2011 03:22:28 GMT

Because no two individuals have the same natural history, it is difficult to determine the extent of damage the liver has experienced. In many cases, the laboratory values and ultrasound images do not accurately determine the degree of fibrosis or scarring that is present. Additionally, the presence of symptoms (fatigue) does not correlate with liver damage. Because of these factors, I believe a liver biopsy yields the greatest amount of information to make subsequent decisions regarding treatment.

The decision to perform a liver biopsy will be determined after all aspects of your care are reviewed in detail. Dr. Galati and Dr. Khaderi will make sure you understand the risks and benefits of a liver biopsy.

View Dr. Galati performing a liver biopsy here.

What is the natural history of hepatitis C?

Sat, 19 Feb 2011 03:17:41 GMT

The natural history is the expected course in a particular disease. In the majority of diseases, it is well known what will occur when someone has a disease and receives no treatment. Hepatitis C does not always follow a particular set of rules. It is estimated that if left untreated, hepatitis C has the potential to progress to cirrhosis in 15% of the cases over a 20-25 year span. Individuals who consume alcohol or have other diseases of the liver may develop cirrhosis in a shorter period of time. There are many factors that affect the natural history of hepatitis C, all of which need to be discussed with the patient.

Neutropenia (low white blood cells)

Tue, 18 Dec 2007 23:11:52 GMT

Similar to a drop in hemoglobin related to ribavirin, interferon caused a drop in white blood cells (WBC), manufactured in the bone marrow. Hite blood cells are used to fight infections in the body. If the WBC drops below an acceptable value, G-CSF (filgrastin) may be used. This stimulated the bone marrow to produce WBC, raising their value above acceptable limits. Similar to ribavirin, it seems beneficial to maintain the appropriate dose of interferon rather than dose reduce. If the WBC is below a critical level, therapy may be reduced or discontinued. G-CSF is associated with certain adverse reactions including skin rash, bone pain, muscle aches, and an exacerbation of psoriasis.

Anemia

Tue, 18 Dec 2007 23:11:34 GMT

Anemia is a very predictable complication of therapy, usually due to ribavirin. Ribavirin causes a hemolytic anemia, damaging red blood cells, which are later removed from the body resulting in the anemia. Symptoms of anemia include increasing fatigue, shortness of breath, lightheadedness, and dizziness. A significant complication of anemia is myocardial ischemia, which can lead to heart failure or a heart attack. For this reason, anemia is treated aggressively.

Reducing the dose of ribavirin usually results in a rise in hemoglobin and improvement in the anemia. This dose reduction in ribavirin may jeopardize the final result of therapy and a lack of viral clearance. It has been generally accepted to treat the anemia without reducing the dose of ribavirin. This is accomplished by making use of erythropoietin.

Erythropoietin is a protein naturally made in the body, which regulates red blood cell production in the bone marrow. It has been successfully manufactured nearly identical to the form in the human body and used in an assortment of conditions for the past 10 years. It is safe and well tolerated. It is very effective in treating the anemia seen with ribavirin use.

The use of erythropoietin not only increases hemoglobin, but also improves upon the fatigue reported in these patients. In most situations, the dose of ribavirin can be maintained, increasing the likelihood of clearing the virus. Blood transfusion is rarely required, but may be an option. Monitoring the effects of erythropoietin requires more frequent blood tests, usually on a weekly basis. Once erythropoietin is used, it is generally used the entire duration of therapy. It is given by weekly injection similar to the interferon.

Headaches

Tue, 18 Dec 2007 23:10:23 GMT

Minor headache complaints generally respond to remaining well hydrated and over the counter preparations such as acetaminophen and non-steroidal anti-inflammatory agents, such as ibuprofen. Patients that have a history of migraine headaches may find that there will be an exacerbation of these headaches once therapy with interferon and ribavirin begin. If they have been on prior therapy for these migraines it may be ineffective.

It will be recommended that in such situations, consultation from a neurologist or headache specialist will be required to continue on with anti-viral therapy. If such a specialist has already evaluated you, we will need to work closely with them to organize a specific plan of care for you.

Nasal Congestion

Tue, 18 Dec 2007 23:10:02 GMT

Nasal congestion is an uncommon complaint, but if present, can be annoying. Symptomatic relief can be obtained with over the counter medications, such as Claritin-D. Remain well hydrated, and avoid cigarette smoke and other nasal and sinus irritatants.

Nausea

Tue, 18 Dec 2007 23:09:45 GMT

Nausea on its own is difficult to treat. There are so many other causes for nausea that this complaint on its own may require a visit to the office. Results vary, but over the counter medications such as Zantac or Pepcid-AC may help. If not, we may recommend other prescription strength medications to reduce stomach acid. There are other classes of drugs that specifically address nausea, but as stated above, this may require a visit to the office for evaluation.

Mouth Ulcers

Tue, 18 Dec 2007 23:09:31 GMT

Some patients are prone to mouth ulcers, which can be rather painful. This may contribute to reduced calories and weight loss (see anorexia). My personal recommendation is to use Kenalog Orabase Dental Paste, which requires a prescription. There are other lesions that affect the mouth so it may require a quick visit to the office before we fill the prescription for you.

Heart Burn/Indigestion

Tue, 18 Dec 2007 23:09:14 GMT

Many patients develop an upset stomach during therapy. If they gave symptoms of gastroesophageal reflux (GERD), symptoms may get worse. Typically, over the counter agents work, such as Zantac or Pepcid-AC. Maalox or Mylanta may also alleviate symptoms. Prescription strength medications such as Nexium, Protonix, or Acifex may be needed. Avoid going to bed with a full stomach, and I recommend at least 4 hours after your last meal before going to bed.

Eye Complications

Tue, 18 Dec 2007 23:08:57 GMT

A baseline examination of your eyes is usually ordered prior to starting therapy with interferon, especially in patients with diabetes or hypertension. Be alert for changes in your vision and report them to the office. Changes may occur in the form of red eyes, blurred vision, eye fatigue, or the need for new prescriptions. It may be necessary to discontinue therapy.

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

Notice the slightly ulcerated tip of the hernia. This can lead to infection and rupture.

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

Umbilical Hernia in Cirrhosis

Tue, 21 May 2013 10:01:56 GMT

These hernias can be painful.

varices11

Tue, 21 May 2013 10:01:56 GMT

Small esophageal varices seen at the lower end of the esophagus in a patient with hepatitis C and cirrhosis.

Band Ligated Esophageal Varices

Tue, 21 May 2013 10:01:56 GMT

Notice the scarred mucosa.

Small Gastric Varices

Tue, 21 May 2013 10:01:56 GMT

On a retroflexed view, small varices in the stomach are noted. These cave the capacity to bleed similar to those in the esophagus. Notice the red whale (at 4 O'clock) -a sign of recent hemorrhage.

Gastric AV Malformation

Tue, 21 May 2013 10:01:56 GMT

Small AV malformation in the stomach of a patient with cirrhosis.

Lorem ipsum

2007-08-10T18:51:28Z

Instructor: Instructor

Lorem ipsum